Does Network Health Cover Forteo (Teriparatide)?

What Is Forteo and Why Is Coverage So Complex?

Forteo (teriparatide) is a recombinant human parathyroid hormone fragment (PTH 1-34) that stimulates new bone formation rather than simply slowing bone loss. The FDA approved it in December 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and patients on sustained glucocorticoid therapy [1]. Because it requires daily self-injection, cold-chain storage at 2, 8°C, and carries a black-box warning regarding osteosarcoma risk in rats, insurers categorize it as a specialty drug requiring clinical review before dispensing [2].

The osteosarcoma warning, established at FDA label approval, does not reflect confirmed human risk, but it does restrict cumulative use to 24 months lifetime and prompts additional documentation requirements from payers [2]. That combination of high acquisition cost (wholesale acquisition cost roughly $3,100, $3,400 per month as of 2024) and specialty status means prior authorization is nearly universal, including at Network Health [3].

Network Health is a Wisconsin-based regional insurer offering commercial, Medicare Advantage, and Medicaid-managed care plans. Its prescription drug formularies are updated annually each January, so tier placement and cost-sharing for Forteo may shift from year to year. Members should download the current formulary PDF from Network Health's website or call the pharmacy benefits line (number on the back of the insurance card) before assuming the prior-year coverage still applies.

Teriparatide's clinical justification for specialty coverage is substantial. The Fracture Prevention Trial (N=1,637 postmenopausal women) showed teriparatide 20 mcg/day reduced new vertebral fractures by 65% (RR 0.35 to 95% CI 0.22, 0.55, P<0.001) and nonvertebral fragility fractures by 53% compared to placebo at a median 21-month follow-up [4]. Those numbers explain why endocrinologists and rheumatologists advocate strongly for coverage approval even when step therapy hurdles slow initial access.

How Network Health Formularies Categorize Forteo

Network Health, like most regional carriers, uses a tiered drug formulary. Specialty drugs typically land on Tier 4 or Tier 5, which carry the highest cost-sharing, often expressed as a percentage (coinsurance) rather than a flat copay. On Network Health commercial plans, specialty coinsurance commonly runs 20 to 33% of the drug's negotiated cost after deductible, which can translate to hundreds of dollars per month even with insurance [5].

The specific tier for teriparatide changes based on the plan type.

Commercial plans. Forteo is listed as a specialty drug requiring prior authorization. Cost-sharing figures vary by plan design. A member on a high-deductible health plan will owe full cost until the deductible is met, then coinsurance on specialty drugs.

Medicare Advantage and Part D plans. For Network Health Medicare Advantage members, teriparatide falls under Medicare Part D specialty tier rules. The Centers for Medicare and Medicaid Services define specialty drugs as those costing more than $940 per month (2024 threshold) [6]. Medicare Part D imposes tiered cost-sharing that, under the Inflation Reduction Act's redesigned benefit beginning in 2025, caps out-of-pocket drug spending at $2,000 per calendar year [7]. That cap meaningfully changes the financial calculation for seniors on Forteo.

Medicaid managed care. Network Health administers Wisconsin Medicaid plans. Wisconsin Medicaid covers teriparatide but requires prior authorization aligned with DHS criteria, typically severe osteoporosis (T-score <-3.0 or documented fragility fracture) plus documented contraindication or failure of bisphosphonate therapy [8].

The table below summarizes typical Network Health coverage tiers by plan type. Confirm with the current formulary because these figures reflect general 2024 plan structures, not a guarantee of current benefit design.

| Plan Type | Typical Tier | Cost-Sharing | Prior Auth | |---|---|---|---| | Commercial PPO/HMO | Specialty (Tier 4-5) | 20 to 33% coinsurance | Yes | | Medicare Advantage Part D | Specialty Tier | Capped at $2,000/year OOP in 2025 | Yes | | Medicaid Managed Care | Covered with restrictions | Low or $0 copay if approved | Yes |

Prior Authorization: What Network Health Requires

Prior authorization for Forteo through Network Health generally requires the prescribing clinician to document several specific clinical criteria. Getting familiar with these before submitting the PA form saves significant back-and-forth time.

Diagnosis confirmation. The member must have a confirmed diagnosis of osteoporosis, typically supported by dual-energy X-ray absorptiometry (DXA) showing a T-score of -2.5 or below, or by a documented low-trauma (fragility) fracture regardless of T-score [9]. The National Osteoporosis Foundation guidelines specify that pharmacological treatment is indicated when the 10-year hip fracture probability is 3% or greater, or the 10-year major osteoporotic fracture probability is 20% or greater, using the FRAX tool [9].

Step therapy documentation. Network Health, consistent with most commercial payers, requires documented trial and failure of at least one first-line antiresorptive agent before approving an anabolic agent like teriparatide. Alendronate (Fosamax, 70 mg weekly) and risedronate (Actonel, 35 mg weekly) are the agents typically named in step-therapy protocols, because both have strong fracture-reduction evidence [10]. "Failure" is interpreted as continued bone loss (decline in DXA T-score despite 12 months of adherent therapy) or new fragility fracture on treatment. Documented intolerance, such as severe esophageal irritation or atypical femoral fracture risk, also satisfies the step-therapy requirement without completing a full trial [11].

High-risk indicators. Payers often fast-track approval for patients who meet high-risk criteria, bypassing step therapy. These include a T-score at or below -3.5, two or more prior vertebral fractures, hip fracture, or ongoing high-dose glucocorticoid use (prednisone 7.5 mg/day or more for 3 months or longer) [12]. The American Association of Clinical Endocrinology 2022 Clinical Practice Guidelines identify these patients as candidates for anabolic-first therapy [12].

Prescriber type. Network Health may require that the PA originate from or be co-signed by a specialist, typically an endocrinologist, rheumatologist, or geriatrician, for specialty-tier bone agents. Primary care physicians prescribing teriparatide should confirm whether a specialist attestation is needed on the PA form.

Prior osteosarcoma history or Paget disease. These are absolute contraindications per the FDA label, and the PA form typically requires the prescriber to affirmatively certify their absence [2].

What Happens After You Submit the PA

Network Health, as an insurer subject to Wisconsin state insurance regulations, must respond to standard prior authorization requests within 3 business days for non-urgent cases and 1 business day for urgent clinical situations [13]. Federal law under the No Surprises Act and the 2024 CMS prior authorization rule (effective January 2026 for MA plans) will require real-time electronic PA responses for routine requests [14].

If the initial PA is approved, the specialty pharmacy partner will contact the member to coordinate 28-day or 90-day supply shipment with temperature-controlled packaging.

If the PA is denied, Network Health must provide a written explanation citing the specific clinical criterion not met. The member and prescriber have the right to file a formal appeal. Wisconsin law requires insurers to complete internal appeals within 30 days for standard requests [13]. If the internal appeal fails, members can request an independent external review through the Wisconsin Office of the Commissioner of Insurance [13].

Appeals that include a letter of medical necessity from the treating physician citing the specific fracture data (for example, the Fracture Prevention Trial result of 65% vertebral fracture reduction with teriparatide [4]) and the AACE 2022 guideline recommendation for anabolic-first therapy in severe osteoporosis have a higher approval rate than appeals without supporting literature [15].

Cost Assistance When Coverage Falls Short

Even with PA approval, specialty-tier coinsurance can leave patients with monthly out-of-pocket costs that make adherence difficult. Several programs can help.

Lilly Cares Foundation. Eli Lilly's patient-assistance program provides Forteo at no cost to qualifying patients who meet income criteria (generally household income at or below 400% of the federal poverty level and no adequate insurance coverage for the drug). Applications are available at Lilly's official patient-assistance portal or by calling 1-800-545-5979 [16].

Lilly Insulin Value Program (commercial copay card). For commercially insured patients who do not qualify for free drug, Lilly offers a copay assistance card that can reduce monthly out-of-pocket costs. Copay cards are not applicable to government-funded insurance such as Medicare or Medicaid [16].

Medicare Extra Help (Low Income Subsidy). Medicare Part D enrollees with limited income and resources can qualify for Extra Help, which reduces Part D premiums, deductibles, and cost-sharing to nominal amounts. The Social Security Administration estimates that Extra Help saves beneficiaries an average of $5,300 per year on drug costs [6].

State Pharmaceutical Assistance Programs. Wisconsin does not operate a state pharmaceutical assistance program for Medicare beneficiaries as of 2025, but the Wisconsin Institute for Healthy Aging maintains a SeniorCare program for residents with income below 240% of the federal poverty level that covers certain drugs including bone agents [17].

340B pricing. Patients receiving care at federally qualified health centers or certain hospital outpatient departments that participate in the 340B Drug Pricing Program may access teriparatide at substantially reduced cost. Eligibility is institution-specific [18].

Biosimilars and Alternatives to Consider

No AB-rated generic teriparatide existed on the U.S. market as of early 2025, but two products compete in the anabolic and antiresorptive categories.

Bonsity (teriparatide-tpvd). Bonsity is an FDA-approved biosimilar to Forteo, cleared in June 2021 [19]. It contains the identical 20 mcg/day teriparatide sequence. Network Health may place Bonsity on a lower specialty tier than Forteo, or may require biosimilar substitution as a condition of coverage. Biosimilar interchangeability designation would allow pharmacist-level substitution without a new prescription; check the FDA's Purple Book for current interchangeability status [19].

Tymlos (abaloparatide). Abaloparatide 80 mcg/day subcutaneous injection is a PTHrP analogue approved by the FDA in April 2017 for postmenopausal women with osteoporosis at high fracture risk [20]. The ACTIVE trial (N=2,463) showed abaloparatide reduced new morphometric vertebral fractures by 86% versus placebo (P<0.001) and nonvertebral fractures by 43% versus placebo [20]. Network Health formularies may place abaloparatide on a different tier than teriparatide, so comparing both drugs' coverage at open enrollment can affect total annual cost.

Romosozumab (Evenity). For patients with very high fracture risk, romosozumab 210 mg monthly (two 105 mg subcutaneous injections) is an anabolic/antiresorptive agent approved by the FDA in April 2019 [21]. The FRAME trial (N=7,180) showed romosozumab reduced new vertebral fractures by 73% at 12 months versus placebo [22]. Network Health prior authorization for romosozumab carries cardiovascular risk exclusion criteria (history of MI or stroke in prior 12 months), consistent with the FDA black-box warning [21].

Oral bisphosphonates as step therapy. If step therapy is required before anabolic therapy, alendronate 70 mg weekly has the strongest long-term fracture data. The FIT trial showed alendronate reduced hip fracture by 51% in women with a prior vertebral fracture (RR 0.49 to 95% CI 0.23, 0.99) [10]. Risedronate 35 mg weekly showed similar hip fracture reduction in the HIP trial [23].

Documenting the Transition Off Forteo

The FDA label limits teriparatide to 24 cumulative months of use across a lifetime [2]. After completing a course, patients must transition to an antiresorptive agent to preserve the bone gained during anabolic therapy. The Endocrine Society Clinical Practice Guideline (2019) recommends transitioning to a bisphosphonate or denosumab (Prolia, 60 mg subcutaneous every 6 months) at the conclusion of teriparatide therapy, because bone mineral density gains are partially lost within 12 to 18 months if no follow-on therapy is used [24].

Denosumab may require its own PA from Network Health. Abrupt discontinuation of denosumab carries a rebound fracture risk; the Endocrine Society guideline specifies transitioning from denosumab to a bisphosphonate after stopping denosumab to prevent this rebound [24]. Network Health PA requests for sequential therapy (teriparatide followed by bisphosphonate or denosumab) should reference this guideline explicitly to document clinical necessity [24].

How to Appeal a Coverage Denial Effectively

A denial letter from Network Health will cite a specific criterion the submission did not satisfy. Effective appeals address that criterion directly rather than resubmitting the original PA without changes.

The prescribing physician should prepare a letter of medical necessity that includes:

1. The patient's DXA T-score, FRAX 10-year fracture probability, and fracture history.
2. Documentation of step therapy: the agent used, duration, dose, and outcome (continued bone loss or intolerance).
3. A direct citation to the AACE 2022 guidelines recommending anabolic-first therapy for T-score at or below -2.5 with fracture or T-score at or below -3.0 [12].
4. The fracture-reduction evidence from the Fracture Prevention Trial (65% vertebral, 53% nonvertebral reduction) [4].
5. A statement certifying absence of contraindications (prior osteosarcoma, Paget disease, open epiphyses, prior radiation therapy involving the skeleton, hypercalcemia) [2].

The appeal packet should also include the DXA scan report and any imaging confirming fractures. Wisconsin's Office of the Commissioner of Insurance accepts external review requests for denied PA appeals at no cost to the member [13].

Monitoring Requirements During Teriparatide Therapy

Network Health, through its specialty pharmacy partners, may require periodic monitoring documentation to continue authorizing refills. Standard clinical monitoring during teriparatide therapy includes:

Serum calcium 1 to 4 weeks after initiation, because teriparatide transiently raises serum calcium in roughly 11% of patients in clinical trials [4]. Repeat DXA at 12 to 18 months of therapy to document response. Serum creatinine and estimated GFR before initiation, given that teriparatide is not recommended in patients with severe renal impairment (creatinine clearance <35 mL/min) [2].

The Endocrine Society recommends checking 25-hydroxyvitamin D levels before and during therapy, targeting a serum level of at least 30 ng/mL, because adequate vitamin D and calcium intake (1,000, 1 to 200 mg/day elemental calcium) support anabolic bone formation [24]. Network Health medical policies may explicitly list these monitoring parameters as conditions of continued PA approval.